{"data":{"type":"company_profile","id":29542,"entity_id":"wefunder:company:29542","attributes":{"canonical_url":"https://wefunder.com/neurocarrus","generated_at":"2026-06-09T20:22:17Z","updated_at":"2026-06-09T05:00:09Z","entity_ids":{"company":"wefunder:company:29542","slug":"wefunder:company_slug:neurocarrus"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-09T20:22:17Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-09T05:00:09Z","as_of":"2026-06-09T20:22:17Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-09T05:00:09Z","as_of":"2026-06-09T20:22:17Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-06-03T21:06:38Z","as_of":"2026-06-09T20:22:17Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-06-03T21:06:38Z","as_of":"2026-06-09T20:22:17Z","confidence":"medium"}}},"company":{"id":29542,"entity_id":"wefunder:company:29542","slug":"neurocarrus","name":"Neurocarrus","tagline":"Treating Neurodegenerative Disease and Pain \r\nWithout Addiction","elevator_pitch":"Since 2017 the opioid epidemic has been classified as\u0026nbsp;national emergency. We're developing a non-opioid drug to treat pain without risk of addiction. So far\u0026nbsp;we've shown promising results\u0026nbsp;in animal trials and are fundraising to continue pre-clinical development.\u0026nbsp;","story":"Neurocarrus top scientific publications:Animal efficacy and safety studiesTargeting, mechanism, and efficacy studiesDrug design and engineering studies","location":"Monterey, CA","website":"https://neurocarrus.com/","total_amount_raised":544228,"total_investors":615,"is_funded":true,"is_active":true,"quality_score":2,"related_urls":["https://wefunder.com/neurocarrus","https://neurocarrus.com/"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/29542/xxl_blob.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/29542/large_cropped_n.jpg","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/29542/standard_blob.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/29542/standard_blob.jpg"},"links":{"company_url":"https://neurocarrus.com/","linkedin_url":"https://linkedin.com/company/neurocarrus","facebook_url":"https://www.facebook.com/neurocarrus/"},"highlights":[],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"Drug candidate N-001 provides relief from acute pain in animals caused by inflammation or surgery."},{"index":2,"claim_id":"claim-fact-2","value":"Neurocarrus has built a pipeline of drugs using the APOLLO targeting and delivery system."},{"index":3,"claim_id":"claim-fact-3","value":"N-001, NL-17, N-19a treat acute, migraine and chronic pain by sensory neuron targeting."},{"index":4,"claim_id":"claim-fact-4","value":"The APOLLO drugs use a unique manufacturing process to discourage competitors."},{"index":5,"claim_id":"claim-fact-5","value":"There is a massive market for the treatment of Neurodegenerative disease and pain around the world."},{"index":6,"claim_id":"claim-fact-6","value":"Neurocarrus has a strong track record of non-dilutive funding from federal and state government."},{"index":7,"claim_id":"claim-fact-7","value":"Founder has been working in the space for 25+ years trouble shooting commercial biologicals."},{"index":8,"claim_id":"claim-fact-8","value":"Patents issued and pending on exclusively licensed technology in both the U.S. and select countries."}],"team":[{"id":318737,"entity_id":"wefunder:company_role:318737","user_entity_id":"wefunder:user:185640","role":"founder","name":"Paul Blum","title":"Co-founder/CEO","bio":"30+ years in cell engineering and microbiology, focused on protein drug development. Paul is full time CEO of Neurocarrus in Monterey, California. He is a serial inventor and was an endowed university professor.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/318737/square_cropped_paul.jpg?1745360767","profile_url":"https://wefunder.com/paulblum","linkedin_url":"https://linkedin.com/in/blum-paul","related_urls":["https://wefunder.com/paulblum"]},{"id":3856440,"entity_id":"wefunder:company_role:3856440","role":"employee","name":"Derek Allen","title":"Research Scientist","bio":"Ph.D. focused on protein drug development with emphasis on protein synthesis and purification. Also specialized in bioassays and potency studies.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/3856440/square_blob.jpg?1717453753","linkedin_url":"https://linkedin.com/in/derek-allen-2b57a6b3/","related_urls":[]},{"id":342466,"entity_id":"wefunder:company_role:342466","role":"employee","name":"Jianguo Cheng, MD, Ph.D","title":"Board Member","bio":"Professor and Director, Cleveland Clinic; Past President, American Academy of Pain Medicine. Highly active in research and pain medicine and strongly supported by NIH. Also an active editor in top pain journals.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/342466/square_cropped_j.jpg?1717453753","linkedin_url":"https://www.linkedin.com/in/jianguo-cheng-md-phd-fipp-66331137/","related_urls":[]},{"id":3867080,"entity_id":"wefunder:company_role:3867080","role":"employee","name":"Bruce McDonald, JD","title":"Board Member","bio":"Partner in the intellectual property group at Smith, Gambrell \u0026amp; Russell, LLP; member of the District of Columbia Bar. Specialized in trademark law and intellectual property litigation, particularly negotiation of licensing agreements.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/3867080/square_blob.jpg?1717453753","related_urls":[]},{"id":3867081,"entity_id":"wefunder:company_role:3867081","role":"employee","name":"Mark Blum, JD","title":"Board Member","bio":"Mark is an attorney licensed in California who practices law in California since 1986. For the past three years, he has continued his role as a shareholder, managing member and practicing attorney at Horan Lloyd.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/3867081/square_blob.jpg?1741116744","related_urls":[]},{"id":3872247,"entity_id":"wefunder:company_role:3872247","user_entity_id":"wefunder:user:4149782","role":"employee","name":"Vicky Valverde Salas","title":"Board Member","bio":"Vicky attended MIT majoring in Mathematics, Physics and Biology. He earned an M.D. from the U. Madison Wisconsin Medical School and trained in Family Medicine at Case Western Reserve. For the past 20 years he ran his own medical Primary Care Clinic.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/3872247/square_blob.jpg?1745360767","profile_url":"https://wefunder.com/vicky.valverde.salas","personal_url":"https://neurocarrus.com","related_urls":["https://wefunder.com/vicky.valverde.salas","https://neurocarrus.com"]}],"featured_investors":[{"id":8840,"entity_id":"wefunder:company_investor_profile:8840","investor_profile_id":112263,"investor_profile_entity_id":"wefunder:investor_profile:112263","subject_entity_id":"wefunder:user:83595","name":"Kurt Stahlfeld","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTA4MDE4LCJwdXIiOiJibG9iX2lkIn19--22b19a1480a3de062e46534ae989db04f5320534/filename","profile_url":"https://wefunder.com/kurtstahlfeld","endorsement_quote":"I believe that Neurocarrus has the potential to revolutionize pain management. Paul and his team have created an incredibly clever drug the produces long lasting pain relief with no side effects or possibility of addiction. Neurocarrus’s N-001 has the potential to become the new standard of care for pain management, improving patient outcomes while eliminating the risk of opioid addiction. With backing from the National Institutes of Health, Neurocarrus is well on their way to changing the world of pain management and capturing a large portion of a market that approaches $80B/year.","investment_total":17000,"investment_info":"Invested $15,000 this round \u0026 $2,000 previously","is_lead_investor":true,"related_urls":["https://wefunder.com/kurtstahlfeld"]}],"investor_memos":[],"tab_counts":{"posts":0,"ask_questions":67,"featured_investors":1,"faq_entries":5},"active_fundraises":[{"id":66105,"entity_id":"wefunder:fundraise:66105","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"safe","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":50000.0,"minimum_target":"50000.0","maximum_target":"618000.0","funding_started_at":"2024-06-12T01:23:08Z","funding_closed_at":"2026-05-01T03:59:59Z","auto_close_at":"2026-05-01T03:59:59Z"},{"id":66106,"entity_id":"wefunder:fundraise:66106","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"ttw","security_type":"equity","currency":"USD","testing_the_waters":true,"min_purchase":100,"max_purchase":9,"funding_target":618000.0,"minimum_target":"50000.0","maximum_target":"618000.0","funding_started_at":"2023-08-16T17:05:29Z"},{"id":20538,"entity_id":"wefunder:fundraise:20538","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"safe","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":600000.0,"minimum_target":"55000.0","maximum_target":"600000.0","funding_started_at":"2018-10-31T17:32:56Z","funding_closed_at":"2019-04-19T04:01:23Z","auto_close_at":"2019-04-19T03:59:59Z"}],"latest_fundraise":{"id":66105,"entity_id":"wefunder:fundraise:66105","state":"successful","offering_type":"4(a)(6)","structure":"safe","testing_the_waters":false,"can_invest_now":false,"funding_started_at":"2024-06-12T01:23:08Z","funding_closed_at":"2026-05-01T03:59:59Z","terms":{"eb":null,"nb":"$11.25M","txt":"valuation cap"}},"recent_posts":[],"q_and_a":[{"id":270845,"entity_id":"wefunder:comment:270845","question":"Paul, Neurocarrus has a very needed drug that can replace opioid based ones without addiction.. When do you think you can complete clinical trials? Have invested again as I believe this will be a blockbuster....","author_name":"Venkatraman Swaminathan","votes":4,"created_at":"2023-12-07T03:11:28Z","canonical_url":"https://wefunder.com/neurocarrus#question-270845","answers":[{"id":284631,"entity_id":"wefunder:comment:284631","answer":"Thank you Ven. Our current Phase II SBIR $2.78 M award will get us to IND filing. IND filing enables us to start clinical trials. Before that we will request federal assistance for phase I trials.","author_name":"Paul Blum","votes":2,"created_at":"2024-06-03T21:30:22Z"}]},{"id":262189,"entity_id":"wefunder:comment:262189","question":"Hi Paul/Neurocarrus, first off I want to say I'm a fan of Neurocarrus. I invested in your previous round and just reserved a spot in the current (September 2023) round. I have a couple comments/questions: 1. I think you are undervaluing Neurocarrus. The previous round was raised at a valuation of $7.5M, the current round has a listed valuation of $8M. Since the first round Neurocarrus has received the Phase I SBIR, demonstrated the efficacy of N-001 in mice, and brought on new staff. Investors want to see a return on their funds and the 7% increase in valuation over the past 3 years could definitely turn off potential investors. Valuations of early stage raises are clearly highly subjective (or pulled from thin air) but for Neurocarrus increasing the valuation of this round by say 50% is completely justified, would make current investors happy, and probably increase what you can raise in this round. 2. Include clickable links to the recent publications. For anyone interested, this is the study from Nature Scientific Reports published a couple months ago: https://www.nature.com/articles/s41598-023-38618-4 3. Are you pursuing other SBIRs? DoD could be interested in N-001 for battlefield medicine, NSF funds all sorts of projects, different call from NIH, etc. 4. Technical question: N-001 reduces pain levels by reducing actin remodeling. Actin has many function beyond pain signaling, is there any concern that N-001 could cause side effects by interfering with these other functions? Thanks, Kurt","author_name":"Kurt Stahlfeld","votes":4,"created_at":"2023-09-14T15:58:35Z","canonical_url":"https://wefunder.com/neurocarrus#question-262189","answers":[{"id":262723,"entity_id":"wefunder:comment:262723","answer":"Hello Kurt, thank you for the questions! Here are responses: 1. Neurocarrus raised its valuation today from $8M to $11.25M based on investor advice and successful preclinical data reducing drug development risk. 2. Thank you for the suggestion, we have added clickable links to our three publications on our Wefunder page. 3. We are currently pursuing additional SBIR funding opportunities. 4. This is a great question! Our previous data have shown that at our dosing, N00-1 is able to inhibit the pain signaling through our actin modification without resulting in neuron death or major morphological changes, and that the actin modification activity is reversible. Our studies to date on safety have not shown any evidence of harmful side effects in animal models, but further safety testing will be important. Actin has been a historical target for pain control, early pharmacologic efforts have shown it as an effective target for pain relief. But all previous attempts were done through small molecule, non-targeted drugs that led to side effects because they were altering actin in non neuronal cells. Our added targeting for N-001 eliminates these off-target effects that result in side effects.","author_name":"Paul Blum","votes":2,"created_at":"2023-09-18T22:03:14Z"}]},{"id":56263,"entity_id":"wefunder:comment:56263","question":"Hi Paul, when will the clinical trials take place? and when will we expect some results from these?","author_name":"Muhamad Faizul Ramli","votes":4,"created_at":"2019-07-01T12:35:51Z","canonical_url":"https://wefunder.com/neurocarrus#question-56263","answers":[{"id":194905,"entity_id":"wefunder:comment:194905","answer":"We hope clinical trials will be in 2 years, depending on preclinical funding levels.","author_name":"Paul Blum","votes":1,"created_at":"2022-03-02T23:45:29Z"}]},{"id":294080,"entity_id":"wefunder:comment:294080","question":"I am not sure if I am misunderstanding something. On the slide related to Intellectual Property it talks about several patents that have been issued or are pending. Then there is a bullet point that states, Neurocarrus exclusively licensed these patents for all-fields-of-use along with a sublicense option. Who owns N-001 and the related patents? Did Neurocarrus develop and own N-001 and the related patents or is Neurocarrus a licensee? If so, what is the length of time of the exclusive license?","author_name":"Dennis Kluk","votes":3,"created_at":"2024-10-13T05:39:09Z","canonical_url":"https://wefunder.com/neurocarrus#question-294080","answers":[{"id":295737,"entity_id":"wefunder:comment:295737","answer":"Hello Dennis, the two issued patents are owned by U .Nebraska. That is why they are licensed. N-001 was invented by me and my coworkers at that university while I was a professor there. The license is in perpetuity. FYI: As you can see in my recent update, the newly filed patent application about the utility of N-001 for migraine treatment will be wholly owned by Neurocarrus.","author_name":"Paul Blum","votes":0,"created_at":"2024-11-04T22:18:54Z"}]},{"id":274842,"entity_id":"wefunder:comment:274842","question":"Full-year EXPAREL net product sales was $536.9 million in 2022, compared with $506.5 million in 2021. Can N-001 do better than this?","author_name":"Venkatraman Swaminathan","votes":3,"created_at":"2024-01-27T04:44:36Z","canonical_url":"https://wefunder.com/neurocarrus#question-274842","answers":[{"id":284630,"entity_id":"wefunder:comment:284630","answer":"We certainly hope so particularly if N-001 duration of action continues to exceed that of EXPAREL.","author_name":"Paul Blum","votes":2,"created_at":"2024-06-03T21:30:20Z"}]},{"id":295799,"entity_id":"wefunder:comment:295799","question":"Will Neurocarrus benefit from the NOPAIN Act, or only after full FDA approval...?","author_name":"Ronald Cunningham","votes":2,"created_at":"2024-11-06T14:21:17Z","canonical_url":"https://wefunder.com/neurocarrus#question-295799","answers":[{"id":295805,"entity_id":"wefunder:comment:295805","answer":"Hello Ronald, Our drug would have to get FDA approval first then it could qualify for the Nopain act.","author_name":"Paul Blum","votes":1,"created_at":"2024-11-06T17:28:18Z"}]},{"id":293809,"entity_id":"wefunder:comment:293809","question":"I know too much on valuation comps. 11.25 mil valuation is too high for a pre-revenue company here. What's the total paid in capital for the company- only about $3.6 million and you haven't even submitted an IND yet? How do you rationalize this valuation? I do find the product interesting, although an injection doesn't sound practical. Can you talk more about the injection approach as well as the patch approach? The patch application sounds way more exciting and practical. About how many years until the company is producing revenues? I saw in the video you estimate $250 million at some point and even more than that later down the line. What's the timeline to possibly reach these sorts of numbers? It's hard to see the upside in this company at a 11.25 mil valuation because even if you reach sales in say two years, and do $100k, $1mil, or even $10mil, the valuation of the company would likely be between the $40-50 mil range at best, but there's a large unknown. You need to raise more funding- minimum of $500k which shouldn't be an issue but upwards of $10 mil or more if doing your own manufacturing. This is a big unknown and big potential hinderance to the company if it's the $10 mil number. Also, It's funny that @Kurt Stahlfeld posted Sept. 2023 that a low, private, market return can turn away investors, but really if you want investors to jump in early you need to make it attractive and underprice or appropriately price the valuation. I may possibly jump on board on this one at the 11.25 mil price simply because of the space it's in and the new application, but again, I don't love the idea of the injection route. Imagine injecting yourself every 8/12/24 hours. I had two shoulder surgeries this summer and was prescribed Oxycodone. I took it around the clock as prescribed. I could only imagine the inconvenience and dreaded-ness in having to inject yourself to relieve pain. Shedding light on the patch more and the injection- how they're administered, who they're administered by, how often administered, any further clarity here would be much appreciated. At the end of the day, if the company is successful and has an exit value of $50/100mil or possibly unlikely so hits unicorn status, in any of these successful cases, there's an immaterial difference between $11.25 mil valuation and say an $8 mil valuation, which seems to be previously posted and discussed.","author_name":"Michael Nadler","votes":2,"created_at":"2024-10-09T22:59:04Z","canonical_url":"https://wefunder.com/neurocarrus#question-293809","answers":[{"id":295740,"entity_id":"wefunder:comment:295740","answer":"Hello Michael, The company's valuation is based on several conventional methods including that used by IndieBio and its parent, SOSV, the largest startup investor in the world. It is typical for drug development startup companies because of the large jumps in valuation that accompany key milestones. About how the drug is administered, yes by injection like most drugs for severe pain except opioids. Alternatively, patches can work as well. Frequency of taking the drug is key. Our preclinical animal data show one dose lasts up to two weeks putting N-001 in a class all its own. With additional funding, this may be extendable. Overall, we want to target the drug to the location of the body experiencing pain and avoid systemic exposure. This is already done because the drug only affects sensory neurons. Targeting is the wave of the future in drug development.","author_name":"Paul Blum","votes":0,"created_at":"2024-11-04T22:55:00Z"}]},{"id":293463,"entity_id":"wefunder:comment:293463","question":"Is this drug the human equivalent of the canine drug Librela with respect to its method of action?","author_name":"Glenn Ephraim","votes":2,"created_at":"2024-10-03T14:18:29Z","canonical_url":"https://wefunder.com/neurocarrus#question-293463","answers":[{"id":295741,"entity_id":"wefunder:comment:295741","answer":"Hello Glenn, Librela is an antibody that targets nerve growth factor, so no, the Neurocarrus drug is very very different.","author_name":"Paul Blum","votes":1,"created_at":"2024-11-04T22:56:37Z"}]},{"id":289504,"entity_id":"wefunder:comment:289504","question":"Please post any big updates under the update section. Curious investors are unable to see any update information.","author_name":"Adam Sampson","votes":2,"created_at":"2024-08-05T01:11:26Z","canonical_url":"https://wefunder.com/neurocarrus#question-289504","answers":[{"id":295742,"entity_id":"wefunder:comment:295742","answer":"Hello Adam, just posted a major update about the new finding that the Neurocarrus drug may treat migraines.","author_name":"Paul Blum","votes":0,"created_at":"2024-11-04T22:57:15Z"}]},{"id":278263,"entity_id":"wefunder:comment:278263","question":"Any updates on this? I reserved a spot for this round in September and there have been no updates/progress for the round since October of last year..?","author_name":"Matt Avalon","votes":2,"created_at":"2024-03-08T03:33:39Z","canonical_url":"https://wefunder.com/neurocarrus#question-278263","answers":[{"id":284629,"entity_id":"wefunder:comment:284629","answer":"Hello Matt, all private investors were sent multiple email updates recently.","author_name":"Paul Blum","votes":0,"created_at":"2024-06-03T21:30:17Z"}]},{"id":49825,"entity_id":"wefunder:comment:49825","question":"Hi, Paul. When do you believe revenue will really start to take off?","author_name":"Craig J. Vom Lehn","votes":2,"created_at":"2019-04-17T14:16:44Z","canonical_url":"https://wefunder.com/neurocarrus#question-49825","answers":[{"id":49850,"entity_id":"wefunder:comment:49850","answer":"After successful clinical trials.\u0026nbsp;","author_name":"Paul Blum","votes":1,"created_at":"2019-04-17T16:39:25Z"}]},{"id":33593,"entity_id":"wefunder:comment:33593","question":"Fascinating MOA. I am a retired endocrinologist and treating diabetic neuropathic pain is very challenging. N-001 looks very promising for this indication. My question is foot pain is diffuse covering a large area or most of the foot. Will a single patch work? Or how do you envision treating this condition? Also what is your plan for treating joint pain? Will this be SQ injections around the entire joint, i.e. how far does a SQ injection of N-001 penetrate? Also joint and low back pain tend to be chronic. I assume that patients will need to visit their doctor on a relatively frequent basis to treat chronic pain (getting injections of N-001)? Thanks.","author_name":"Rick Schiebinger","votes":2,"created_at":"2019-01-19T02:54:54Z","canonical_url":"https://wefunder.com/neurocarrus#question-33593","answers":[{"id":35703,"entity_id":"wefunder:comment:35703","answer":"Treatment of diabetic neuropathy would emphasize patch application at the primary location of pain. Patches could be any size and if more area needs treatment, more patches could be applied. As for joint pain, yes the drug would need to be delivered more deeply to the tissue. We don't know about depth of penetration other than as it relates to the needle penetration. Chronic pain treatment would likely required repeated visists but at the moment in animal models one dose lasts for 2 weeks.","author_name":"Paul Blum","votes":0,"created_at":"2019-02-26T01:40:24Z"}]},{"id":32439,"entity_id":"wefunder:comment:32439","question":"As compared to traditional opiates, how quickly does the treatment start to make pain disappear? And how long does it last? Other pros / cons vs opiates?","author_name":"Jordan Frank","votes":2,"created_at":"2018-12-27T03:15:57Z","canonical_url":"https://wefunder.com/neurocarrus#question-32439","answers":[{"id":32504,"entity_id":"wefunder:comment:32504","answer":"This is an important question. Because opioids must be taken frequently (usually daily) we concentrated on testing our drug for its duration of action relieving pain. Recently we found a single dose lasts 13 days. Now we are testing how rapidly the drug works. Recent results indicate pain relief within 2-3 hr but we have more testing to do. The key benefit of our drug relative to opioids is the lack of addiction and other side effects. Our drug acts locally on pain because it is administered locally (like an anaesthetic). It cannot cross into the brain, it does not act systemically.","author_name":"Paul Blum","votes":3,"created_at":"2018-12-28T19:48:46Z"}]},{"id":31458,"entity_id":"wefunder:comment:31458","question":"Hello, I have just found your company information and I would love to become an investor as I am someone who can benefit from the treatment. How would someone as myself see about becoming one of the humans you test this on when it gets approved. I am a Chronic Pain patient and tired of all the meds I am currently on. This is a great adventure and I hope to be involved on both ends. Lisa","author_name":"Lisa Garcia","votes":2,"created_at":"2018-12-06T18:48:39Z","canonical_url":"https://wefunder.com/neurocarrus#question-31458","answers":[{"id":31480,"entity_id":"wefunder:comment:31480","answer":"Hi there I completely understand your interest, me too, also a chronic pain person and partly why I’m going to get this drug available\u0026nbsp;for pain. Clinical trials are the earliest time the drug can be tested. I’m\u0026nbsp;first in line because I want to benefit and derisk it,\u0026nbsp;and since you asked you can be second!","author_name":"Paul Blum","votes":6,"created_at":"2018-12-07T00:15:07Z"}]},{"id":332308,"entity_id":"wefunder:comment:332308","question":"Investor comment for those on the sidelines: Neurocarrus is a stand out of sorts in that they can meet a giant unmet need (the need to stop using / eliminate opiates), they have intellectual property protection, they have a product that is well proven at an early stage (animal testing has proven it stops pain for the needed amount of time to eliminate the use of opiates post-surgery), and they have a very clean cap table at only $4M invested to date. The Team’s ability to attract grant funding has been instrumental to keeping a tight cap table, and that story only gets better as the next ~ $500K invested unlocks another non-dilutive $2.7M grant. No investment is a sure thing, but Neurocarrus looks like a low risk bargain if you can afford to wait until they get through enough clinical trials to get acquired or get to market.","author_name":"Jordan Frank","votes":1,"created_at":"2026-04-29T00:03:55Z","canonical_url":"https://wefunder.com/neurocarrus#question-332308","answers":[]},{"id":330641,"entity_id":"wefunder:comment:330641","question":"More than 6 years ago you raised at $8 million valuation. Why is at only $11.25m now?","author_name":"Venkatraman Swaminathan","votes":1,"created_at":"2026-04-10T01:31:32Z","canonical_url":"https://wefunder.com/neurocarrus#question-330641","answers":[{"id":330683,"entity_id":"wefunder:comment:330683","answer":"Hello Ven, Good question. Valuation has increased proportionally to investment AND non dilutive grant awards. The valuation will increase further with additional investment and non dilutive awards. Upon receipt of a successful IND application, the company will have realized a significant reduction in risk and valuation will increase again.","author_name":"Paul Blum","votes":0,"created_at":"2026-04-10T16:20:27Z"}]},{"id":327917,"entity_id":"wefunder:comment:327917","question":"I am interested in investing in this company. I believe this could be a game changer to treating neurodegenerative disease and pain without the worries of becoming addicted to the current drugs being used. My concern is that I haven't seen any recent updates as to the progress. The last post was in October 2025. Are there any updates since then? Also, it shows that this company is 100% profitable but have not generated any revenue. What are your plans to continue being profitable and to start generating revenue?","author_name":"bugg logg","votes":1,"created_at":"2026-03-16T23:47:41Z","canonical_url":"https://wefunder.com/neurocarrus#question-327917","answers":[{"id":329124,"entity_id":"wefunder:comment:329124","answer":"Hello bugg logg, The company generated $100,000 in 2025 and is on track for 2026. Recent progress will appear in a general update shortly and describes new preclinical efficacy (benefit) results in a procedure that simulates lower limb surgery.","author_name":"Paul Blum","votes":0,"created_at":"2026-03-26T22:51:13Z"}]},{"id":316090,"entity_id":"wefunder:comment:316090","question":"Thanks Paul for answering my questions. I got few more 1) I see this is open from 2019 or so based on the comments here... why do u think it's taking so much 2) Without a product close to production, increasing the valuation after you quoted 8M to 11.25 is NOT working , I believe as investors may think (IMO) 3) Finally you said the product will be avaialble in 2 years around 2024 , can you explain why the delay... thanks MN","author_name":"Murali NAGARAJAN","votes":1,"created_at":"2025-10-01T16:07:29Z","canonical_url":"https://wefunder.com/neurocarrus#question-316090","answers":[{"id":329125,"entity_id":"wefunder:comment:329125","answer":"Hello Murali Nagarajan. This is our second raise started in 2024. The 2019 raised closed that year. Drug development is slow as expected, timelines are dependent on raises. In 2023 the company was awarded $2,700,000 to advance on of its pain assets to IND filing. We are on track to do that this year. Next is human testing and more raises. If phase 1 trials succeed, we anticipate significant increases in valuation, outlicensing (revenue generation) or Pharma acquisition.","author_name":"Paul Blum","votes":0,"created_at":"2026-03-26T22:55:50Z"}]},{"id":315401,"entity_id":"wefunder:comment:315401","question":"Paul , Got few questions.... 1) Why is this much slowness in the development. Your first raise was in 2019 and it's been nearly 6 years since then 2) Can this be made pill form as many r not comfortable with injection. 3) Why is headcount very less only 2... Again I see tremendous potential with N001 but the slowness (as I perceive) is causing hesitation for me as there r other folks who r ahead in getting FDA approval as an alternative for Opiod... Thanks MN","author_name":"Murali NAGARAJAN","votes":1,"created_at":"2025-09-20T19:48:35Z","canonical_url":"https://wefunder.com/neurocarrus#question-315401","answers":[{"id":316088,"entity_id":"wefunder:comment:316088","answer":"Hi Murali, 1) the drug development process is slow and the rate of development is proportional to the amount invested. Outside of our 2019 and current raise, we were awarded over $4M by federal and state non dilutive funding thereby leveraging private investment. 2) no, our drugs are administered locally, they are not oral drugs and do not act systemically (like narcotics). They are designed to act only at the location of the pain and that is why they are non addictive. 3) Headcount is low but consultants and subcontractors (not counted on this platform) is large. 4) recently approved or getting close to approval alternatives to narcotics (opioids) are ALL anesthetics. Anesthetics are untargeted drugs meaning their off side effects PREVENT repeated us. Neurocarrus drugs are all highly targeted drugs and superior in design. Also, Neurocarrus drugs are biologics meaning proteins not small molecules. Small molecules are easy to make, biologics take longer to get the manufacturing completed. But the public LOVES biologics as they include therapeutic antibodies. Paul","author_name":"Paul Blum","votes":0,"created_at":"2025-10-01T14:57:14Z"}]},{"id":309649,"entity_id":"wefunder:comment:309649","question":"Hi Derek, Seems interesting. What's the best way to reach you to discuss investment?","author_name":"Y S","votes":1,"created_at":"2025-06-13T17:18:25Z","canonical_url":"https://wefunder.com/neurocarrus#question-309649","answers":[{"id":309654,"entity_id":"wefunder:comment:309654","answer":"Hi Yaacov, you can email either of us at derek@neurocarrus.com or paul@neurocarrus.com to discuss investment.","author_name":"Paul Blum","votes":0,"created_at":"2025-06-13T18:16:01Z"}]},{"id":308574,"entity_id":"wefunder:comment:308574","question":"Your pitch page says that you have met your initial goal for this round butter still taking investments. What is the total amount that you desire to raise at this valuation? When do you anticipate a follow up round? What are the next major milestones on the path to completion of your clinical trials and subsequent commercialization? What do you antiquate as the size of your phase 1 trial? How many dosing levels would you expect to evaluate in your safety and efficacy trials. Good luck in your forts, this would certainly fulfill and unmet need.","author_name":"K Tucker Andersen","votes":1,"created_at":"2025-05-25T00:07:42Z","canonical_url":"https://wefunder.com/neurocarrus#question-308574","answers":[{"id":310218,"entity_id":"wefunder:comment:310218","answer":"That is correct. Our current raise cap is $640K with an option to increase. For lead asset N-001, the next milestone is to complete GMP manufacturing along with safety and efficacy testing then file an IND. For our other assets NL-17 (migraine) and N-19a (chronic pain), milestones are out-licensing and co-development respectively. For N-001, around 20 for the N-001 Phase 1 trial at 4-8 doses, and 25-40 in Phase II, unless of course we can run a combined phase I/II.","author_name":"Paul Blum","votes":0,"created_at":"2025-06-25T17:05:28Z"}]},{"id":305218,"entity_id":"wefunder:comment:305218","question":"Hello Neurocarrus Team, I’m Zac Stahlhut with D3VC. We specialize in investment crowdfunding and had a question regarding your regulatory and competitive positioning. With the FDA’s recent approval of Vertex’s JOURNAVX, a selective NaV1.8 inhibitor for pain management, how do you anticipate this influencing your own approval process? Do you foresee any shifts in regulatory expectations or market dynamics that could impact N-001’s pathway to approval and eventual commercialization? Looking forward to your insights!","author_name":"Zac Stahlhut","votes":1,"created_at":"2025-04-02T17:23:03Z","canonical_url":"https://wefunder.com/neurocarrus#question-305218","answers":[{"id":310219,"entity_id":"wefunder:comment:310219","answer":"Hello Zac. About the anesthetic suzetrigine (Journavx), like other anesthetics, the lack of targeting remains a risk factor that distinguishes it from all Neurocarrus drugs therefore our approval process for N-001 (acute pain) should be unaffected. We believe our first-in-class drugs will address unmet need using more direct trial designs that directly compare efficacy to other standards of care.","author_name":"Paul Blum","votes":0,"created_at":"2025-06-25T17:11:28Z"}]},{"id":304801,"entity_id":"wefunder:comment:304801","question":"How has Neurocarrus been affected by recent government changes and cutbacks? What do you expect the impact may be going forward on revenues and the approval process?","author_name":"Dan Schoeffler","votes":1,"created_at":"2025-03-27T19:49:23Z","canonical_url":"https://wefunder.com/neurocarrus#question-304801","answers":[{"id":304803,"entity_id":"wefunder:comment:304803","answer":"Good question. Fortunately Neurocarrus has not been impacted to date.","author_name":"Paul Blum","votes":0,"created_at":"2025-03-27T19:55:11Z"}]},{"id":299224,"entity_id":"wefunder:comment:299224","question":"If you are pre-clinical, where is the revenue coming from? Has the drugs been approved for animal use? When will clinical testing begin?","author_name":"Jarod Rudisill","votes":1,"created_at":"2025-01-01T18:59:00Z","canonical_url":"https://wefunder.com/neurocarrus#question-299224","answers":[{"id":299352,"entity_id":"wefunder:comment:299352","answer":"Hello Jarod, Neurocarrus is well supported by non dilutive government awards for R\u0026amp;D of its candidate pain drug. These funds support current efforts to apply for an IND (investigational new drug) to begin clinical testing (estimated end of this year). Investor funds raised on Wefunder are used for operating, legal, business and other costs. Good question about animal use applications! Because the Neurocarrus drug works well in animals, there has been interest from animal drug companies about development opportunities.","author_name":"Paul Blum","votes":0,"created_at":"2025-01-02T23:12:25Z"}]},{"id":297997,"entity_id":"wefunder:comment:297997","question":"How will this drug be delivered? Is there any data with human tissue/cells?","author_name":"Mark Smith","votes":1,"created_at":"2024-12-13T18:10:52Z","canonical_url":"https://wefunder.com/neurocarrus#question-297997","answers":[{"id":298010,"entity_id":"wefunder:comment:298010","answer":"Hi Mark, drug delivery will be by injection or a patch at the pain location. About humans, yes we have positive results on cultured cells and tissues showing the drug mechanism operates well.","author_name":"Paul Blum","votes":0,"created_at":"2024-12-13T20:26:22Z"}]}],"faq":[{"question":"What was the valuation on your 12/17 priced round? Why crowdfunding vs. traditional public biotech listings on the OTC or Canadian Venture exchanges? Do you have IP that's defendable? Thanks for your time, I like what you're trying to accomplish!","answer":"Hello Barnaby, happy to answer these. Our valuation in our 12/17 round was 3 million. We chose crowdfunding on Wefunder due to the number of people who have contacted us individually and expressed a desire to invest at a small scale. Many acquaintances expressed interest to us since our inception, but we haven't had the time to individually work through each contract. Using Wefunder, we can give each party a full picture and make sure they are completely informed, while providing a simple way..."},{"question":"Interesting molecule that from the limited information appears to work by blocking pain neurotransmission-Is this then a drug for neuropathic or somatic pain or both? secondly venturing in to phase 1-3 trials requires huge funding and we have seen many biotech start up firms o...","answer":"Hello Palliankal. Thanks for reaching out. Your understanding is essentially correct: our drug targets overactive sensory neurons, and has the potential to treat many kinds of peripheral pain. So to answer your first question, it is a drug for both kinds of pain. In regards to your second question, I assume you're asking about how we will fund clinical trials. We anticipate U.S. government grant support for Phase 1 trials (especially given newly allocated funding for development of new, non-o..."},{"question":"What is your exit strategy? Do you intend to pay a dividend past Phase three?","answer":"Hello Craig. We plan to partner with a larger pharmaceutical company at or after Phase 1 clinical trials. This will be either through a licensing agreement for N-001, or an acquisition of our company. Dividend payments, or other form of profit-sharing, will depend on the structure of our exit, but may come sooner than Phase 3."},{"question":"Hi, does the SAFE converts to preferred stock or common stock?","answer":"Good question. SAFE converts to preferred stock. Paul"},{"question":"Mr. Blum- How long(years) do you foresee before a larger pharmaceutical company purchases your drug. Asking as an investor for time frame. Thank you and good luck!","answer":"We could expect our drug to be purchased (or licensed) within 1-2 years corresponding to stages in its development. Stage one is when the FDA (Food and Drug Agency) approves our IND (Investigational New Drug) application because it means we can start human clinical trials. Stage two is when we complete Phase I human trials with a successful outcome, that would be that our drug is safe."}]}}}